Clinical Laserthermia Systems Announces Initiation of Prostate Cancer Clinical Study in collaboration with U.S based HALO Diagnostics
Lund, Sweden – November 7, 2023 – Clinical Laserthermia Systems AB (publ) (“CLS” or “the Company”) today announces that their US subsidiary CLS Americas and US based HALO Diagnostics, a leader in precision diagnostics and image-guided therapies (HALO Dx), has entered an agreement to initiate a clinical study using the TRANBERG Thermal Therapy System to perform image-guided focal laser ablation (FLA) of low-to-intermediate risk prostate cancer in 25 patients.Data from these patients treated over the next 6-8 months will be entered into a patient registry where their long-term follow up will